Diferencia entre revisiones de «Template:Epiglottitis Antibiotics»
(Add pediatric immunocompetent and immunocompromised dosing) |
|||
| (No se muestran 2 ediciones intermedias del mismo usuario) | |||
| Línea 1: | Línea 1: | ||
Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae | Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae | ||
====Immunocompetent==== | ====Immunocompetent==== | ||
* | *{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR | ||
* | *{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR | ||
* | *{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR | ||
* | *{{AntibioticDose|disease=Epiglottitis|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}} | ||
*Consider | *Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref> | ||
====Immunocompromised==== | ====Immunocompromised==== | ||
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans | Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans | ||
* | *{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}} | ||
====Pediatric Immunocompetent==== | |||
*{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=50-100mg/kg IV daily (max 2g)|context=Pediatric Immunocompetent|population=Pediatric}} (first line) OR | |||
*{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=50mg/kg IV q8hrs (max 2g/dose)|context=Pediatric Immunocompetent|population=Pediatric}} OR | |||
*{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=50mg/kg IV q6hrs (max 3g/dose)|context=Pediatric Immunocompetent|population=Pediatric}} | |||
*Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric, MRSA risk|population=Pediatric}} if risk of [[MRSA]] | |||
====Pediatric Immunocompromised==== | |||
*{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=50mg/kg IV q8hrs (max 2g)|context=Pediatric Immunocompromised|population=Pediatric}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric Immunocompromised|population=Pediatric}} | |||
Revisión actual - 12:52 20 mar 2026
Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae
Immunocompetent
- Ceftriaxone 2gm IV once daily (first line) OR
- Cefotaxime 2gm (50mg/kg) IV three times daily OR
- Ampicillin/Sulbactam 3g (50mg/kg) IV q 6 hours OR
- Levofloxacin 750mg IV once daily
- Consider Vancomycin 15-20mg/kg IV to any of the above if risk of MRSA[1]
Immunocompromised
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
- Cefepime 2g (50/kg) IV q8 hours AND Vancomycin 15mg/kg IV q6 hours
Pediatric Immunocompetent
- Ceftriaxone 50-100mg/kg IV daily (max 2g) (first line) OR
- Cefotaxime 50mg/kg IV q8hrs (max 2g/dose) OR
- Ampicillin/Sulbactam 50mg/kg IV q6hrs (max 3g/dose)
- Consider Vancomycin 15mg/kg IV q6hrs if risk of MRSA
Pediatric Immunocompromised
- Cefepime 50mg/kg IV q8hrs (max 2g) AND Vancomycin 15mg/kg IV q6hrs
- ↑ Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.